Skip to content
Back to HAE

Haemonetics Corp

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
1
Purchases
0
Sales
1
Purchase value
$0.00
Sale value
$101.15K

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Farris Maryanne MaunsellVP, Chief Accounting Officer
4
Filed Nov 13, 2026Period of report Nov 11, 20260000313143-26-000155
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 11, 2026
Common StockF3F1836$120.99$101.15K5,828Direct
Filing footnotes · 4
  1. F1This number includes unvested restricted stock units ("RSUs") previously reported.
  2. F2Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.87 to $121.10, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
  4. F4Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.